cp wire

CP Wire Articles

Landos Biopharma Initiates Ph I Trial of First-in-class Oral Treatment for IBD
  • BT-11 is a first-in-class, oral, locally-acting small molecule
  • BT-11 has demonstrated a 90% reduction of inflammation by acting locally in the gut mucosa in 4 validated mouse models... read more
Thu, 07/12/18 - 09:17 am
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
  • Trial is Enrolling Patients with Colorectal, Non-Small Cell Lung, Pancreatic or Head and Neck Cancers
  • Earlier study demonstrated an encouraging response rate in patients with... read more
Thu, 07/12/18 - 08:58 am
Opdivo Gains New Approval in Combination with Yervoy
  • Approved in patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a... read more
Wed, 07/11/18 - 10:11 am
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant



  • Ninlaro maintenance therapy resulted in a statistically significant improvement in progression-free survival (PFS) versus placebo.
  • Ninlaro has orphan drug status in... read more
Wed, 07/11/18 - 09:56 am
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
  • Tucatinib has been granted orphan drug status for the treatment of breast cancer patients with brain metastases.
  • Overall response rate (ORR) was 61% for Ph Ib triplet study
  • ... read more
Wed, 07/11/18 - 09:37 am

Pages